Lack of antimicrobial activity by the antiretroviral drug nevirapine against common bacterial pathogens

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 8, 2009, Pages 3606-3607

  Jackson, J Brooks ^a   Dick, James ^b   Tekle, Tsigereda ^b   Simmons, Antoine ^b   Carroll, Karen C ^b  

^a Carnegie Building ^*  (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENTAMICIN; NEVIRAPINE; PENICILLIN G;

ANTIMICROBIAL ACTIVITY; CHEMOPROPHYLAXIS; DRUG TREATMENT FAILURE; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; HUMAN; KLEBSIELLA PNEUMONIAE; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; SHIGELLA FLEXNERI; VIBRIO CHOLERAE;

ANTI-BACTERIAL AGENTS; ANTI-RETROVIRAL AGENTS; BACTERIA; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; HUMANS; NEVIRAPINE; SALMONELLA; SHIGELLA FLEXNERI; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 67749120507     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01583-08     Document Type: Letter

References (5)

1. Elwell, L. P., R. Ferone, G. A. Freeman, J. A. Fyfe, J. A. Hill, P. H. Ray, C. A. Richards, S. C. Singer, V. B. Knick, J. L. Rideout, and T. P. Zimmerman. 1987. Antibacterial activity and mechanism of action of 3′-azido-3′-deoxythymidine (BW A509U). Antimicrob. Agents Chemother. 31:274-280.
2. Kumwenda, N. I., D. R. Hoover, L. M. Mofenson, M. C. Thigpen, G. Kafulafula, Q. Li, L. Mipando, K. Nkanaunena, T. Melbrahtu, M. Bulterys, M. G. Fowler, and T. E. Taha. 2008. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N. Engl. J. Med. 359:119-129.
3. Lim, D., and W. K. Maas. 1989. MicroReview: reverse transcriptase in bacteria. Mol. Microbiol. 3:1141-1143.
4. Shetty, A. K., H. M. Coovadia, M. M. Mirochnick, Y. Maldonado, L. M. Mofenson, S. H. Eshleman, T. Fleming, L. Emel, K. George, D. A. Katzenstein, J. Wells, C. C. Maponga, A. Mwatha, S. A. Jones, S. S. Abdool Karim, and M. T. Bassett for the HIVNET 023 Study Team. 2003. Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly, or weekly in breast-feeding infants from birth to 6 months. J. Acquir. Immune Defic. Syndr. 34:482-490.
5. Six Week Extended-Dose Nevirapine (SWEN) Study Team et al. 2008. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomized controlled trials. Lancet 372:300-313.